Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Xencor Inc.
DescriptionBispecific mAb targeting PD-1 and cytotoxic T-lymphocyte associated protein 4 (CTLA4; CD152) using Xencor's Xtend Fc domain technology
Molecular Target Programmed cell death 1 (PD-1) (PDCD1) (CD279) ; Cytotoxic T-lymphocyte associated protein 4 (CTLA4) (CD152)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today